RNA Therapeutics Market Growth & Trends Report: From USD 20.32 Billion in 2025 to USD 45.35 Billion by 2034

According to the latest report by Straits Research, the global RNA therapeutics market size is valued at USD 20.32 billion in 2025, and is projected to grow from USD 22.15 billion in 2026 to USD 45.35 billion by 2034, registering a compound annual growth rate (CAGR) of 9.37% between 2026 and 2034.
The expansion of the RNA therapeutics market is being driven by rising incidences of cancers and rare genetic disorders, and by significant advancements in RNA delivery platforms that are improving tissue targeting and enabling a new generation of treatments.

Read the full report to uncover trends and forecasts: https://straitsresearch.com/report/rna-therapeutics-market

Introduction:
RNA therapeutics represent a groundbreaking frontier in medicine encompassing technologies such as messenger RNA (mRNA), RNA interference (RNAi), antisense oligonucleotides and other RNA-based modalities. These therapies offer precise targeting of disease at the molecular level, opening up treatment possibilities for cancers, genetic diseases, infectious diseases and more. The RNA platform success in vaccines during the COVID-19 pandemic has accelerated investment and trust in this therapeutic class.

As the clinical pipeline expands and delivery technologies mature, the RNA therapeutics market is transitioning from early adoption to rapid commercialisation, offering meaningful opportunities for biotech companies, major pharmas, and specialized service providers.

Key Market Trends & Insights:
Regional dominance: North America held a dominant share of the global market in 2025, accounting for approximately 43.79%. This is attributed to regulatory approvals of RNAi products, well-established biotech ecosystems, and strong funding infrastructure.

Fastest growth region: The Asia-Pacific region is expected to grow at the fastest pace (CAGR ~11.64%) due to increasing cancer prevalence, growing investment in liver-targeted RNAi therapies, and rising clinical trial activity.

By therapy type: In 2025, the mRNA therapeutics segment held the largest share of ~31.42%, driven by approved vaccines and a high number of candidates in clinical development.

By application: Oncology is poised for the fastest CAGR (~10.27%), driven by the increasing global burden of cancer, adoption of RNA-based therapies for cancer management and pipeline momentum.

Market Drivers:
Rising incidence of cancer and genetic disorders: With more than 2 million new cancer cases in the U.S. in 2024 (for example), the demand for novel treatments including RNA therapeutics is increasing.

Strong funding and research support: Governments, academic institutions and industry are accelerating RNA platform development. For example, in April 2025 the U.S. NIH announced more than USD 200 million in grants for RNAi-based platforms.

Technological advancements in delivery platforms: Delivery has long been the hurdle for RNA therapies; breakthroughs in lipid nanoparticles, targeted conjugates, self-amplifying RNA and circular RNA therapies are unlocking new possibilities and expanding addressable indications.

Market Restraints:
High development and manufacturing cost: RNA therapies require high-purity nucleotides, advanced lipid or conjugate systems, and scalable manufacturing. For instance, raw materials can account for ~60% of mRNA manufacturing cost.

Regulatory and clinical risk: While the RNA field is advancing rapidly, many modalities are still early stage clinical risk, long trials and safety/efficacy validation add complexity and cost.

Delivery and targeting complexity: Tissue-specific delivery remains challenging, particularly for non-hepatic targets. Off-target effects, immune activation and biodistribution remain issues.

Get your free sample to analyze key market segments: https://straitsresearch.com/report/rna-therapeutics-market/request-sample

Market Opportunities:
Expanding pipeline of mRNA and RNAi treatments: Leading vaccine developers and biotech innovators are shifting focus from vaccines toward RNA-based treatments for oncology, rare diseases, metabolic conditions and more.

Next-generation RNA platforms: Circular RNA (circRNA), self-amplifying RNA (saRNA), and other novel delivery platforms offer improved dose efficiency, enhanced durability and potentially lower cost all of which boost market opportunity. For instance, a circRNA therapy entered trial in June 2024 for oncology.

Emerging markets in Asia-Pacific and Latin America: As healthcare infrastructure improves and local biotech ecosystems mature, new geographic growth lanes are opening for RNA therapeutics.

Regional Analysis:
North America remains the largest market, attributed to mature regulatory structure, significant biotech investment, and high incidence of chronic and genetic diseases.

Asia-Pacific is emerging as the fastest-growing region due to increasing local innovation, rising contract development/manufacturing organisations (CDMOs), and government support for RNA therapies (for example, a Chinese company secured approval for an mRNA-LNP cell therapy in 2024).

Europe, Middle East, Africa (MEA) & Latin America also offer opportunities as biotech ecosystems expand, and regulatory frameworks adapt to advanced therapies.

Segmentation Insights:
By therapy type: mRNA, RNAi, antisense oligonucleotides and other RNA-based modalities each have distinct dynamics; mRNA leads in share currently, while RNAi and antisense show strong growth potential.

By application: Oncology leads today and is set to continue expanding due to significant unmet need; other growing segments include genetic disorders, cardiovascular and infectious diseases.

By end-user: Hospitals & clinics dominate, given that many RNA therapies are administered in specialised care settings; however research institutes, CDMOs and biotech service providers offer growth support.

Competitive Landscape:
Key players in the RNA therapeutics market :
Moderna, Inc.
Pfizer Inc.
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Novartis AG
Sanofi
CureVac N.V.

Buy the full report for strategic insights and datasets: https://straitsresearch.com/buy-now/rna-therapeutics-market

Analyst Insight:
A paradigm shift is under way in medicine, where RNA therapeutics are no longer just the next wave they are becoming central to how disease is treated," says a lead analyst at Straits Research. "With mRNA vaccines proving the model, the next frontier is therapeutic RNAs for cancer, rare diseases and high-value conditions. Organisations that build delivery, data-driven pipeline and global manufacturing will lead the USD 45 billion market by 2034.

Conclusion:
In summary, the RNA therapeutics market is poised for substantial expansion over the next decade. With a forecast to more than double from USD 20.32 billion in 2025 to USD 45.35 billion by 2034, the market will be shaped by modality innovations, delivery breakthroughs, rising disease burden and global adoption. Stakeholders across biotech, pharma, manufacturing and diagnostics should prioritise RNA-platform capabilities, regulatory readiness and g

Contact Us :
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

About Us :
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

This release was published on openPR.